Parathyroidectomy: still the best choice for the management of severe secondary hyperparathyroidism.

التفاصيل البيبلوغرافية
العنوان:	Parathyroidectomy: still the best choice for the management of severe secondary hyperparathyroidism.
المؤلفون:	Ramos LGF; Universidade Nove de Julho, São Paulo, SP, Brazil., Cortes DDPVR; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Serviço de Nefrologia, São Paulo, SP, Brazil., Reis LMD; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Serviço de Nefrologia, São Paulo, SP, Brazil., Montenegro FLM; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Cirurgia de Cabeça e Pescoço, São Paulo, SP, Brazil., Arap SS; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Cirurgia de Cabeça e Pescoço, São Paulo, SP, Brazil., Brescia MDG; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Cirurgia de Cabeça e Pescoço, São Paulo, SP, Brazil., Custódio MR; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Serviço de Nefrologia, São Paulo, SP, Brazil., Jorgetti V; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Serviço de Nefrologia, São Paulo, SP, Brazil., Elias RM; Universidade Nove de Julho, São Paulo, SP, Brazil.; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Serviço de Nefrologia, São Paulo, SP, Brazil., Moysés RMA; Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Serviço de Nefrologia, São Paulo, SP, Brazil.
المصدر:	Jornal brasileiro de nefrologia [J Bras Nefrol] 2024 Apr-Jun; Vol. 46 (2), pp. e20230024.
نوع المنشور:	Journal Article
اللغة:	English; Portuguese
بيانات الدورية:	Publisher: Sociedade Brasileira de Nefrologia Country of Publication: Brazil NLM ID: 9426946 Publication Model: Print Cited Medium: Internet ISSN: 2175-8239 (Electronic) Linking ISSN: 01012800 NLM ISO Abbreviation: J Bras Nefrol Subsets: MEDLINE
أسماء مطبوعة:	Publication: São Paulo : Sociedade Brasileira de Nefrologia Original Publication: São Paulo, Brazil : Associação Medica Brasileira
مواضيع طبية MeSH:	Hyperparathyroidism, Secondary/drug therapy , Hyperparathyroidism, Secondary/etiology , Hyperparathyroidism, Secondary/surgery , Renal Insufficiency, Chronic/etiology, Humans ; Cinacalcet/therapeutic use ; Parathyroidectomy/adverse effects ; Retrospective Studies ; Renal Dialysis/adverse effects ; Parathyroid Hormone
مستخلص:	Introduction: Management of secondary hyperparathyroidism (SHPT) is a challenging endeavor with several factors contruibuting to treatment failure. Calcimimetic therapy has revolutionized the management of SHPT, leading to changes in indications and appropriate timing of parathyroidectomy (PTX) around the world. Methods: We compared response rates to clinical vs. surgical approaches to SHPT in patients on maintenance dialysis (CKD 5D) and in kidney transplant patients (Ktx). A retrospective analysis of the one-year follow-up findings was carried out. CKD 5D patients were divided into 3 groups according to treatment strategy: parathyroidectomy, clinical management without cinacalcet (named standard - STD) and with cinacalcet (STD + CIN). Ktx patients were divided into 3 groups: PTX, CIN (cinacalcet use), and observation (OBS). Results: In CKD 5D we found a significant parathormone (PTH) decrease in all groups. Despite all groups had a higher PTH at baseline, we identified a more pronounced reduction in the PTX group. Regarding severe SHPT, the difference among groups was evidently wider: 31%, 14% and 80% of STD, STD + CIN, and PTX groups reached adequate PTH levels, respectively (p<0.0001). Concerning the Ktx population, although the difference was not so impressive, a higher rate of success in the PTX group was also observed. Conclusion: PTX still seems to be the best treatment choice for SHPT, especially in patients with prolonged diseases in unresourceful scenarios.
References:	Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1260-1267. (PMID: 27269300) Clin J Am Soc Nephrol. 2011 Apr;6(4):913-21. (PMID: 21454719) Scand J Surg. 2021 Mar;110(1):66-72. (PMID: 31906794) Curr Opin Nephrol Hypertens. 2017 Nov;26(6):516-522. (PMID: 28985191) J Bras Nefrol. 2020 May 20;42(2):191-200. (PMID: 32459279) Ren Fail. 2019 Nov;41(1):326-333. (PMID: 31014177) Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. (PMID: 30675420) Clin Kidney J. 2019 Mar 18;12(6):871-879. (PMID: 31807302) Nephrol Dial Transplant. 2011 Apr;26(4):1327-39. (PMID: 21148030) Kidney Int. 2015 Aug;88(2):350-9. (PMID: 25786097) Kidney Int. 2004 Jan;65(1):282-8. (PMID: 14675061) Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1282-1296. (PMID: 26912549) Surgery. 2018 May;163(5):1144-1150. (PMID: 29331397) Clin Kidney J. 2022 Feb 23;15(8):1459-1474. (PMID: 35892022) Nephron. 2018;139(3):197-210. (PMID: 29514156) PLoS One. 2013 Aug 05;8(8):e68870. (PMID: 23940515) J Surg Res. 2023 May;285:229-235. (PMID: 36709541) J Bras Nefrol. 2011 Dec;33(4):457-62. (PMID: 22189810) BMC Nephrol. 2013 May 03;14:100. (PMID: 23642012) Surgery. 2019 Jan;165(1):129-134. (PMID: 30415867) J Bras Nefrol. 2019 Jul 18;41(3):336-344. (PMID: 31419274)
المشرفين على المادة:	UAZ6V7728S (Cinacalcet) 0 (Parathyroid Hormone)
تواريخ الأحداث:	Date Created: 20231201 Date Completed: 20240321 Latest Revision: 20240629
رمز التحديث:	20240629
مُعرف محوري في PubMed:	PMC11210536
DOI:	10.1590/2175-8239-JBN-2023-0024en
PMID:	38039492
قاعدة البيانات:	MEDLINE

Full Text Finder

الوصف
تدمد:	2175-8239
DOI:	10.1590/2175-8239-JBN-2023-0024en